brigatinib
UkraineDrugs containing this active substance
-
The drug is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that is ALK-positive. It is used in both treatment-naïve patients and those whose disease has progressed following crizotinib treatment.
Form: tablets, film-coated
Active substance Dosage brigatinib 30 mg ATC: L01ED04
Manufacturer: Takeda Austria GmbH (batch release authorization)
-
The drug is intended for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that is ALK-positive. It is used for both those who have not previously received treatment with ALK inhibitors and for patients whose disease has progressed after the use of crizotinib.
Form: tablets, film-coated
Active substance Dosage brigatinib 90 mg ATC: L01ED04
Manufacturer: Takeda Austria GmbH (batch release authorization)
-
The drug is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that is ALK-positive. It is used in both treatment-naïve patients and those whose disease has progressed following crizotinib treatment.
Form: tablets, film-coated
Active substance Dosage brigatinib 180 mg ATC: L01ED04
Manufacturer: Takeda Austria GmbH (batch release authorization)